



Proopiomelanocortin (POMC) is a 241-amino acid 
polypeptide that is cleaved via prohormone convertase (PC) 
to produce the peptides γ-, β-, α-melanocyte stimulating 
hormone (MSH), adrenocorticotropin hormone (ACTH), 
γ-, β-lipotrophin and endorphins (1). These peptides 
stimulate five different melanocortin receptors (MCR) 
with varying affinity and specificity. Cortisol secretion is 
regulated through MC2R in the adrenal gland while MC1R 
regulates skin pigmentation. MC3R and MC4R regulate 
body weight. 
Congenital POMC deficiency develops due to genetic defects 
in the POMC gene located at Chr.2p23.3. This disorder is 
characterized by early-onset obesity, adrenal insufficiency, 
red hair and decreased skin pigmentation (1,2,3,4). Obesity 
develops as a result of inadequate production of α- and 
β-MSH, which normally activate the MC3R in the arcuate 
nucleus and the MC4R in the paraventricular nucleus and 
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antagonize the action of agouti-related peptide (AgRP) 
(4). The hypocortisolaemia and hypopigmentation are due 
to inadequate stimulation of MC2R and MC1R by POMC-
derived peptides in the adrenal gland and skin, respectively. 
POMC deficiency is rare, but has increased our insight into 
the important role of the leptin-melanocortin pathway in 
energy balance.
Here, we present the clinical characteristics of a patient 
with POMC deficiency due to a mutation in the POMC gene, 
hoping to contribute to a better understanding of the leptin-
melanocortin pathway and to introduce possible treatment 
options. 
Case Report 
This female patient presented at age 2.5 months with 
restlessness, cyanosis, and spasms. She was found to be 
hypoglycaemic with a blood glucose of 31 mg/dL. She was 
born at 39 weeks gestation with a birth weight of 3000 
grams and had no problems during the prenatal or early 
postnatal period. Her mother and father were not related 
and she had a healthy brother aged five years. There was 
no history of relevant disease in the family. Examination 
findings at presentation revealed growth failure (body 
weight: 3700 g, 3rd percentile; height: 51 cm, <3rd percentile; 
head circumference: 35 cm, <3rd percentile) (Figure 
1A), red eyebrows and hair and normal female genitalia. 
Results of further laboratory investigations confirmed the 
hypoglycaemia (blood glucose: 19 mg/dL) and revealed 
mild hyponatraemia with a sodium of 132 mmol/L (135-
143), accompanied by a potassium of 4.8 mmol/L (3.1-5.5), 
mildly elevated aspartate transaminase: 123 U/L (<36) and 
creatinine kinase: 419 U/L (34-204). 
Concomitant with the hypoglycaemic state (34 mgl/dL), 
serum and urinary ketones were low and there was no 
evidence of hyperinsulinaemia or any other metabolic 
cause for the hypoglycemia (serum insulin: 0.11 U/L, 
C-peptide: <0.03 nmol/L, lactate: 2.37 mmol/L (0.49-
2.19), ammonium: 93.5 μmol/L (13.5-42.8), urinary and 
blood amino acids and organic acid profile normal). Total/
indirect bilirubin levels were 3.7/2.4 mg/dL. However, the 
child was hypocortisolaemic (cortisol: <5.51 nmol/L) 
with an undetectable ACTH level (ACTH: <1.1 pmol/L). 
Other anterior pituitary hormones were as follows: growth 
hormone 14.8 μg/L; thyroid-stimulating hormone 1.73 U/L; 
free thyroxine 14.02 pmol/L; prolactin 390 mIU/L (3-24); 
follicle-stimulating hormone <3 U/L (0.1-3.3); luteinizing 
hormone <0.07 U/L (0-1.9). A low-dose ACTH stimulation 
test showed an insufficient cortisol response at 40 minutes 
(12.1 nmol/L). A magnetic resonance imaging (MRI) scan 
of the pituitary gland was normal. A diagnosis of isolated 
central (secondary) ACTH insufficiency, rather than 
panhypopituitarism was made.
Hydrocortisone treatment was initiated which subsequently 
enabled successful control of the hypoglycemia. Due to the 
presence of central adrenal insufficiency together with red 
hair, a genetic analysis of the POMC gene was undertaken. 
A homozygous frameshift mutation, c.206delC (p.P69Lfs*2) 
in the POMC gene was detected (5). This mutation results in 
a downstream frameshift and premature protein truncation, 
removing ACTH and other important peptides and most 
likely completely disrupting POMC function (Figure 1B). 
Following this initial presentation, in subsequent months, 
the child showed rapid increase in growth and developed 
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Figure 1. Weight (left) and height chart (right) of the 
patient showing rapid weight gain after infancy (A). 
Chromatogram showing the homozygous c.206delC 
change that results in a leucine residue (CTG) being 
replaced by a stop codon (TGA) (upper). This mutation 
causes disruption of proopiomelanocortin and prevents 
cleavage of proopiomelanocortin into key peptides such as 
adrenocorticotropin hormone and α-melanocyte stimulating 
hormone (lower) (B)
ACTH: adrenocorticotropin hormone, POMC: proopiomelanocortin, CLIP: 
corticotropin-like intermediate lobe peptide, γLPH: γ-lipotropin, βED: 
β-endorphin, MSH: melanocyte-stimulating hormone
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obesity. At 17 months of age her weight was 16.9 kg 
(>97th percentile), height 80 cm (50th percentile), and head 
circumference 40 cm (75-90th percentile) (Figure 1A). Her 
eyebrows and hair were red (Figure 2). The final steroid 
treatment dose was 8 mg/m2/day. An informed consent 
form for publication was given by the parents. 
Discussion
Congenital isolated ACTH deficiency is a rare condition and 
the symptoms and signs can be nonspecific. However, it can 
be life threatening unless appropriate steroid replacement is 
initiated. POMC is synthesized in the corticotropic cells of 
the pituitary gland by the action of the transcription factor 
TBX19/TPIT. POMC is then cleaved to form ACTH by the 
enzyme PC1 [PC1/3, proprotein convertase subtilisin/kexin 
(PCSK) type 1] following corticotropin-releasing hormone 
stimulation (Figure 1B) (6). Isolated ACTH deficiency can 
result from pathogenic variations of the TBX19 (TPIT), 
PCSK1 (PC1/3) and POMC genes (6).
Although POMC defects were first reported in 1998, 
relatively few children with the condition have been 
reported to date (4). The classic triad of POMC deficiency 
consists of early-onset obesity, central adrenal insufficiency 
and red hair. Hyperphagia (80-99%), cholestasis (30-
79%, at onset), exponential weight gain (100%) and 
adrenal insufficiency (30-79%, at onset) are typically 
observed during the first months of life, but the diagnosis 
may only be established later in some children. Linear 
growth is initially normal, as in our patient, and weight 
gain may not occur initially in a child with uncontrolled 
adrenal insufficiency. However, weight often increases to 
above the 90th percentile by the end of the first year. This 
process likely reflects an insufficiency of hypothalamic 
POMC. Normally, nutrition and energy hemostasis is 
balanced by the complex interaction of POMC and AgRP/
neuropeptide Y (NPY) with MCR in the hypothalamus (Figure 
3) (1,2,3,4). This system is also regulated by peripheral 
polypeptides such as leptin and ghrelin. Our patient showed 
a rapid and early-onset weight gain as a result of this process. 
The weight gain was independent of steroid treatment as 
only a physiological replacement dose of hydrocortisone 
was used and subsequent linear growth rate was stabilized 
on the 50th percentile line, despite ongoing rapid weight 
gain. 
The red hair associated with POMC deficiency is an 
important sign, especially in children from an ancestral 
background of dark hair. However, there are a few reports 
of children with POMC deficiency who do not have red hair 
or where only the roots of the hair are red (6,7,8,9). Other 
children may have red hair initially but this turns brown in 
the first three to four years of life (10).
Other reported features potentially associated with 
POMC deficiency include pale skin (Fitzpatrick type 1) 
due to reduced stimulation of MC1R by MSH; central 
hypothyroidism, possibly due to interactions between POMC 
and thyrotropin-releasing hormone in the hypothalamus 
(10,11,12,13); and hypogonadotropic hypogonadism with 
pubertal growth hormone deficiency reflecting a possible 
direct interaction between POMC and gonadotropin-
Figure 2. General appearance [At appointment (red eyebrows 
and hair) (A), at 1.5 years old (obesity) (B), at 2.5 years old (C)]
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releasing hormone neurons or indirectly via kisspeptin and 
NPY/AgRP. Our patient did not show hypothyroidism, but 
did have pale skin and had a low gonadotropin level in early 
infancy at around the time of the typical “minipuberty”. 
This finding may reflect impaired gonadotropin release so 
it is important to monitor the development of puberty in 
these patients. Transient hyponatraemia has been reported 
with central ACTH insufficiency, as was seen in our patient 
(14). This may reflect decreased free water clearance due to 
hypocortisolaemia, especially with intercurrent infections, 
or a supportive mineralocorticoid effect of cortisol at times 
of stress. Detecting hyponatraemia can sometimes lead to 
a misdiagnosis of primary adrenal insufficiency instead of 
a secondary or central defect. Finally, developmental delay 
with abnormal MRI changes has been reported in one child 
with POMC deficiency. This finding is likely to represent 
the effects of recurrent hypoglycaemia rather than the 
underlying condition itself (15). 
Genetic analysis was useful to establish the diagnosis of 
POMC deficiency. Using a custom adrenal array coupled with 
next generation sequencing we identified a homozygous 
c.206delC mutation in the child (5). This nucleotide deletion 
was confirmed by Sanger sequencing and causes a frameshift 
and premature truncation of the protein at codon 70 
(p.Pro69Leufs2*) (Figure 1B). This mutation results in a POMC 
product that lacks ACTH, α-MSH and other small peptides, 
and may be subject to non-sense mediated decay. A review 
of the literature shows that all reported patients with POMC 
deficiency have homozygous or compound heterozygous 
mutations in the amino-terminal region of the protein that 
result in defective ACTH and α-MSH synthesis. The c.206delC 
change has been reported in two other families in Turkey 
suggesting a founder effect (7). The only established point 
mutation in POMC causing a similar phenotype is p.Arg145Cys 
change that corresponds to a p.Arg8Cys mutation in the ACTH 
peptide (16). This point mutation results in a bioinactive 
form of POMC/ACTH with a clinical phenotype of red hair, 
obesity and central adrenal insufficiency but with elevated 
ACTH levels on biochemical testing. In addition, isolated 
obesity has been reported in carriers of POMC mutations 
or in association with heterozygous point mutations in 
POMC (especially p.Arg236Gly) (7,17,18,19). Overview of 
the clinical and molecular features of patients with POMC 
insufficiency published to date were presented in Table 1 
(Table 1). However, the parents of our child had BMIs of 23 
kg/m2 and 27 kg/m2.
Treatment of POMC deficiency can be challenging. 
Patients require life-long glucocorticoid treatment using 
replacement doses. Mineralocorticoid replacement is not 
required. Hypothyroidism should be monitored and treated 
if present. Early onset obesity can be very difficult to treat 
beyond standard dietary and lifestyle measures, but the 
hyperphagic component is especially challenging. Krude et 
al (10) attempted intranasal ACTH treatment in two index 
cases with the ACTH peptide fragment identical to α-MSH. 
However, ACTH treatment at low doses during the first six 
weeks followed by a high dose (5 mg/day) did not produce a 
significant response in weight loss. Recently, setmelanotide 
(Rhythm Pharmaceuticals, Boston, Massachusetts, USA) has 
been developed as a novel MC4R agonist for the treatment 
of rare genetic disorders of obesity associated with defects 
in the MC4 pathway. This novel therapy is currently in Phase 
II trials in patients with POMC deficiency. 
Figure 3. Cartoon showing potential interactions of 
proopiomelanocortin neurons in appetite regulation. In the 
hypothalamus, nutrition and energy hemostasis is balanced by 
proopiomelanocortin and agouti-related peptide/neuropeptide 
Y through melanocortin receptors. This system is regulated 
by peripheral polypeptides such as leptin, ghrelin, insulin and 
peptide YY. In proopiomelanocortin deficiency, the appetite-
stimulating effect of agouti-related peptide is not balanced by 
the appetite-suppressing effect of proopiomelanocortin. AgRP 
is co-expressed with neuropeptide Y. This peptide increases 
appetite and decreases energy use and metabolism. This 
system is mainly inhibited by leptin and stimulated by ghrelin
NPY: neuropeptide Y, AgRP: agouti-related peptide, POMC: 
proopiomelanocortin, MSH: melanocyte-stimulating hormone, MC4R: 
melanocortin 4 receptors, PPY: peptide YY, GABA: gamma-amino butyric acid
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In summary, we present a Turkish child with POMC 
deficiency due to a potential founder POMC mutation. 
Routine genetic analysis in patients suspected of POMC 
deficiency is recommended not only to guide long-term 
prognosis and tailor the personalized management of these 
patients per se, but also to enable discovery of breakthrough 
treatments for important public health problems such as 
obesity.
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